Introduction：Basic information about CAS 147245-92-9|Glatiramer acetate, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Glatiramer acetate |
|---|
| CAS Number | 147245-92-9 | Molecular Weight | 623.65000 |
|---|
| Density | / | Boiling Point | 385.2ºC at 760mmHg |
|---|
| Molecular Formula | (C9H11NO3.C6H14N2O2.C5H9NO4.C3H7NO2)x.xC2H4O2 | Melting Point | >239°C (dec.) (lit.) |
|---|
| MSDS | / | Flash Point | 186.7ºC |
|---|
Names
| Name | acetic acid,(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid,(2S)-2-aminopentanedioic acid,(2S)-2-aminopropanoic acid,(2S)-2,6-diaminohexanoic acid |
|---|
| Synonym | More Synonyms |
|---|
Glatiramer acetate BiologicalActivity
| Description | Glatiramer acetate, a synthetic analogue of myelin basic protein and an immunomodulating agent, can be used for the research of multiple sclerosis. Glatiramer acetate exhibits strong and promiscuous binding to MHC molecules and consequent competition with various myelin antigens for their presentation to T cells. A further aspect of its action is potent induction of specific suppressor cells of the T helper 2 (Th2) type that migrate to the brain and lead to in situ bystander suppression[1][2][3]. |
|---|
| Related Catalog | Signaling Pathways >>Others >>OthersResearch Areas >>Inflammation/Immunology |
|---|
| In Vitro | Glatiramer acetate (25-100 mg/kg; S.c; 5 days) increase BDNF levels[3]. In huntington’s disease (HD) mouse model, the N171-82Q transgenic mouse line, which exhibits a more rapidly progressing disease course. Glatiramer acetate (1 mg/mouse; s.c.; 5×week) beginning at 8 weeks of age and continuing until 20 weeks of age, which is near the age of death due to the disease. Glatiramer acetate elicited improves performance on several motor function measures. Glatiramer acetate significantly improves the performance of N171-82Q transgenic mice at 15 weeks of age in the rotarod test measured over the course of 4 days[3]. |
|---|
| References | [1]. McKeage K. Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review. CNS Drugs. 2015;29(5):425-432. [2]. Arnon R, et al. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci U S A. 2004;101 Suppl 2(Suppl 2):14593-14598. [3]. Corey-Bloom J, et al. Beneficial effects of glatiramer acetate in Huntington's disease mouse models: Evidence for BDNF-elevating and immunomodulatory mechanisms. Brain Res. 2017;1673:102-110. [4]. Aharoni R, et al. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ [published correction appears in Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12288]. Proc Natl Acad Sci U S A. 2003;100(24):14157-14162. |
|---|
Chemical & Physical Properties
| Boiling Point | 385.2ºC at 760mmHg |
|---|
| Melting Point | >239°C (dec.) (lit.) |
|---|
| Molecular Formula | (C9H11NO3.C6H14N2O2.C5H9NO4.C3H7NO2)x.xC2H4O2 |
|---|
| Molecular Weight | 623.65000 |
|---|
| Flash Point | 186.7ºC |
|---|
| Exact Mass | 623.30100 |
|---|
| PSA | 374.13000 |
|---|
| LogP | 2.14760 |
|---|
| Vapour Pressure | 1.27E-06mmHg at 25°C |
|---|
| InChIKey | FHEAIOHRHQGZPC-KIWGSFCNSA-N |
|---|
| SMILES | CC(=O)O.CC(N)C(=O)O.NC(CCC(=O)O)C(=O)O.NC(Cc1ccc(O)cc1)C(=O)O.NCCCCC(N)C(=O)O |
|---|
| Storage condition | 2-8°C |
|---|
Synonyms
| Glatiramer acetate |
| MFCD04113403 |
| UNII-5M691HL4BO |
| Copolymer 1 |
| Copaxone |
| COP-1 |
